Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Nkarta ( (NKTX) ).
On March 25, 2026, Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company for an at-the-market equity offering of up to $100 million of its common stock, with Stifel acting as sales agent and earning a commission of up to 3% on gross sales proceeds. The shares will be sold from time to time at Nkarta’s discretion under a Form S-3 shelf registration and related prospectus supplement filed the same day with the SEC, providing the company with flexible access to capital while the agreement remains in effect until all shares are sold or the arrangement is otherwise terminated.
Under the terms of the arrangement, Nkarta controls key parameters of each sale, including timing, volume limits per trading day and minimum price thresholds, and sales may be executed on Nasdaq, other trading markets, over-the-counter or via privately negotiated transactions. The structure gives Nkarta a mechanism to raise funding opportunistically in the market to support its business needs, with customary indemnification protections provided to the agent and a legal opinion from O’Melveny & Myers LLP confirming the validity of the shares to be issued.
The most recent analyst rating on (NKTX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Nkarta stock, see the NKTX Stock Forecast page.
Spark’s Take on NKTX Stock
According to Spark, TipRanks’ AI Analyst, NKTX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and significant cash burn), with additional pressure from bearish technical indicators. Valuation provides limited support because negative earnings make P/E less informative and there is no dividend yield.
To see Spark’s full report on NKTX stock, click here.
More about Nkarta
Nkarta, Inc. is a biopharmaceutical company focused on developing cell-based therapies, with its primary activities centered on researching and advancing treatments that leverage engineered immune cells. The company is listed on the Nasdaq Global Select Market and accesses public equity markets as a key component of its capital-raising strategy to fund ongoing operations and clinical development programs.
Average Trading Volume: 759,966
Technical Sentiment Signal: Sell
Current Market Cap: $151.3M
See more data about NKTX stock on TipRanks’ Stock Analysis page.